Table 7.
Randomised controlled trial results reporting the effect of soya isoflavone interventions and equol producer (EP) status on body composition variables*
| First author, year | CHD risk factor measured | Effect of isoflavones on CHD risk factors | Result marker† | Effect of EP status on CHD risk factors | Result marker‡ |
|---|---|---|---|---|---|
| Acharjee et al. (2015)(27) | BMI | The soya intervention had a NS effect on BMI compared with placebo | 0 | EP status had a NS effect on BMI compared with placebo | 0 |
| Nikander et al. (2004)(43) | BW | The isoflavonoid intervention had a NS effect on BW compared with placebo | 0 | EP status had a NS effect on BW after the isoflavonoid intervention | 0 |
| West et al. (2005)(65) | BW | The soya intervention had a NS effect on BW compared with placebo | 0 | EP status had a NS effect on BW after the soya intervention | 0 |
| Wong et al. (2012)(66) | BW, BMI, waist circumference | The soya interventions had a NS effect on the risk factors compared with placebo | 0 | EP status had a NS effect on the risk factors after the soya treatments | 0 |
BW, body weight.
*
Results are first stratified by the impact of EP status and then the impact of the soya isoflavone interventions on each of the lipid risk factors.
†
+, Beneficial effect of soya isoflavones on risk factors of CHD; 0, negligible effect of soya isoflavones on risk factors of CHD; –, adverse effect of soya isoflavones on risk factors of CHD.
‡
+, Beneficial effect of EP status on risk factors of CHD after soya intervention; 0, negligible effect of EP status on CHD risk factors after soya intervention; –, adverse effect of EP status on risk factors of CHD after soya intervention.